journal article·2022-06-16Open access

Effectiveness and Safety of ANTI SARS-CoV-2 Vaccination in Transplant Patients Treated with Immunosuppressants: A Real-World Pilot Study with a 1-Year Follow-Up

Alfredo Caglioti, Vincenzo Rania, Cristina Vocca, Gianmarco Marcianò, Valentina Arcidiacono, Luca Catarisano, Alessandro Casarella, Emanuele Basile, Manuela Colosimo, Caterina Palleria, Daniela Mazzuca, Giulio Di Mizio, Caterina De Sarro, Claudia Pileggi, Giovambattista De Sarro, Luca Gallelli

Applied Sciences· Volume 12· Issue 12

Abstract

SARS-CoV-2 is a betacoronavirus, which induced a severe pandemic infectious disease around the world. Even if several drugs have been suggested for its treatment, to date, the only strategy to reduce the severity of disease is represented by the use of vaccine. However, the lack of pre-marketing evidence in frail patients suggests the necessity of the real-world study of a vaccine benefit–risk profile. In this study, we evaluated the efficacy and the safety of SARS-CoV-2 vaccination in a cohort of 33 patients treated with an immunosuppressant after solid organ transplant. Both CLIA and LS/MS analysis were used to evaluate the levels of immunoglobulin (Ig)G anti SARS-CoV-2 and the therapeutic drug monitoring of immunosuppressant drugs. We documented that SARS-CoV-2 vaccination induced a dose- and gender-related serological response. In particular, in 63.6% of the enrolled patients, we documented a significant serological response at T2, and after a time related decrease, the booster dose induced a serological response in 72.7% of enrolled patients. In conclusion, the vaccine anti SARS-CoV-2 is immunogenic in patients under immunosuppression, and is not related to the development of ADRs. We also suggest that the booster dose could be used to increase the efficacy of the vaccination, particularly in women.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · COVID-19 Clinical Research Studies · Vaccine Coverage and Hesitancy

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Operative Unit of Kidney Diseases and Transplants, Mater Domini University Hospital, 88100 Catanzaro, Italy

Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy

Operative Unit of Microbiology and Virology, Pugliese Hospital, 88100 Catanzaro, Italy

Operative Unit of Clinical Pharmacology, Mater Domini University Hospital, 88100 Catanzaro, Italy

Department of Law, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy

FAS@UMG Research Center, Department of Health Science, School of Medicine, University of Catanzaro, 88100 Catanzaro, Italy

Medifarmagen SRL, University of Catanzaro and Mater Domini University Hospital, 88100 Catanzaro, Italy

References (17)

Show source-provided references
1. Structures and distributions of SARS-CoV-2 spike proteins on intact virions10.1038/s41586-020-2665-2 ↗
2. National Institutes of Health (2022). Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19).
3. Administration of COVID-19 vaccines in immunocompromised patients10.1016/j.intimp.2021.108021 ↗
4. BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response10.1016/j.healun.2021.04.003 ↗
5. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients
6. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients10.1016/j.healun.2021.05.004 ↗
7. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients10.1681/ASN.2021040490 ↗
8. The effects of minocycline on extracellular matrix in patients with chronic venous leg ulcers
9. De Venlafaxine—Propafenone Interaction Resulting in Hallucinations and Psychomotor Agitation10.1345/aph.1K405 ↗
10. Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients10.1111/ajt.16295 ↗
11. Acute kidney rejection after anti-SARS-CoV-2 virus-vectored vaccine—Case report10.1038/s41541-022-00445-5 ↗
12. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy Weak anti—SARS-CoV-2 antibody response after the fi rst injection of an mRNA COVID-19 vaccine in kidney transplant recipients10.1016/j.kint.2021.03.002 ↗
13. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases10.1136/annrheumdis-2021-220289 ↗
14. Humoral and T-cell responses to SARS-vaccination in patients receiving immunosuppression10.1136/annrheumdis-2021-220626 ↗
15. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients10.1001/jama.2021.7489 ↗
16. The X chromosome in immune functions: When a chromosome makes the difference10.1038/nri2815 ↗
17. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients10.1016/j.annonc.2021.04.020 ↗